Apellis Pharmaceuticals, Inc.
Targeted C3 complement inhibitor therapeutics
- Sector
- Biotech
- Headquarters
- CRESTWOOD, KY
- Founded
- 2009
- Latest Form D
- $20M, Aug 2017
- Total capital
- $115M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $115M
- 8 Form D · last Aug 2017
- 110 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 14
- 26 pending · first 2022
- Rank in peer group#77 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 8th filing$20M
- Private capital raisedForm D · SEC · 7th filing$47.1M
- Private capital raisedForm D · SEC · 6th filing$32.1M
- Private capital raisedForm D · SEC · 5th filing$6M
- Private capital raisedForm D · SEC · 4th filing$6M
- Private capital raisedForm D · SEC · 3rd filing$693K
- Private capital raisedForm D · SEC · 2nd filing$1.7M
- Private capital raisedForm D · SEC · 1st filing$1.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#77 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Federico Sinclair GrossiResearcherExecutive OfficerLinked by 1 patent
- A. Sinclair DunlopDirectorNamed in SEC Form D filings
- Alec Sinclair MachielsDirectorNamed in SEC Form D filings
- Bihua Sinclair ChenDirectorNamed in SEC Form D filings
- Cedric FrancoisExecutive Officer, DirectorNamed in SEC Form D filings
- Daniel Sinclair GeffkenExecutive OfficerNamed in SEC Form D filings
Show all 21 people
- David DarstDirectorNamed in SEC Form D filings
- David Darst, Jr.DirectorNamed in SEC Form D filings
- David Sinclair WatsonExecutive OfficerNamed in SEC Form D filings
- Douglas OnsiDirectorNamed in SEC Form D filings
- Gerald ChanDirectorNamed in SEC Form D filings
- Maha Sinclair KatabiDirectorNamed in SEC Form D filings
- Marie-Claude BernalDirectorNamed in SEC Form D filings
- Nicole Sinclair PerryExecutive OfficerNamed in SEC Form D filings
- Pascal DeschateletsExecutive Officer, DirectorNamed in SEC Form D filings
- Robert Sinclair AdelmanDirectorNamed in SEC Form D filings
- Robert Sinclair KimExecutive OfficerNamed in SEC Form D filings
- Sinclair DunlopDirectorNamed in SEC Form D filings
- Stephanie Sinclair O'BrienDirectorNamed in SEC Form D filings
- Stephen GilliesDirectorNamed in SEC Form D filings
- Steven Sinclair AxonExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 14 granted of 40- GrantedViral Vector TherapyUSPTOUS 12,741,036
- PendingCompositions And Methods For Altering Complement ActivationUSPTOApplication 19679108
- PendingComplement InhibitionUSPTOApplication 19145748
Show all 40 patent records
- Viral Vector TherapySep 22, 2026 · US 12,741,036Granted
- Compositions And Methods For Altering Complement ActivationSep 10, 2026 · Application 19679108Pending
- Complement InhibitionJul 30, 2026 · Application 19145748Pending
- Combination Therapy For C3 InhibitionJul 2, 2026 · Application 19244313Pending
- Systems And Methods For Virtual Reality, Augmented Reality, And Mixed Reality Based Visual Function AssessmentJun 11, 2026 · Application 18702594Pending
- Complement Inhibitor Dosing RegimensMar 12, 2026 · Application 18707159Pending
- Cell-reactive, Long-acting, Or Targeted Compstatin Analogs And Uses ThereofMar 5, 2026 · Application 19229679Pending
- Dosing RegimensJan 20, 2026 · US 12,528,836Granted
- Dosing Regimens And Related Compositions And MethodsNov 4, 2025 · US 12,458,695Granted
- Cell-reactive, Long-acting, Or Targeted Compstatin Analogs And Related Compositions And MethodsSep 11, 2025 · Application 18905256Pending
- Dosing Regimens And Related Compositions And MethodsMay 29, 2025 · Application 19054702Pending
- Polypeptides For Complement InhibitionMay 8, 2025 · Application 18282664Pending
- Dosing Regimens And Related Compositions And MethodsMay 6, 2025 · US 12,290,566Granted
- Rnas For Complement InhibitionMar 18, 2025 · US 12,251,395Granted
- Rnas For Complement InhibitionMar 6, 2025 · Application 18724567Pending
- Treatment Of Complement-mediated DisordersJan 2, 2025 · Application 18563184Pending
- Treatment Of Geographic AtrophyJan 2, 2025 · Application 18690607Pending
- Complement InhibitionOct 31, 2024 · Application 18573634Pending
- Dosing Regimens And Related Compositions And MethodsAug 29, 2024 · Application 18386542Pending
- Genomic Editing Of ComplementJul 4, 2024 · Application 18563588Pending
- Genomic Editing Of ComplementApr 4, 2024 · Application 18266464Pending
- Cell-reactive, Long-acting, Or Targeted Compstatin Analogs And Uses ThereofMar 7, 2024 · Application 18133372Pending
- Dosing RegimensFeb 20, 2024 · US 11,903,994Granted
- Dosing Regimens And Related Compositions And MethodsDec 19, 2023 · US 11,844,841Granted
- Methods Of Treating Eye DisordersNov 30, 2023 · Application 18027331Pending
- Methods Of Treating Chronic Disorders With Complement InhibitorsAug 1, 2023 · US 11,712,460Granted
- Cell-reactive, Long-acting, Or Targeted Compstatin Analogs And Uses ThereofMay 30, 2023 · US 11,661,441Granted
- Rnas For Complement InhibitionMar 30, 2023 · Application 17798339Pending
- Cell-reactive, Long-acting, Or Targeted Compstatin Analogs And Related Compositions And MethodsMar 23, 2023 · Application 17673703Pending
- Treatment Of Paroxysmal Nocturnal HemoglobinuriaMar 9, 2023 · Application 17791194Pending
- Cell-penetrating Compstatin Analogs And Uses ThereofMar 9, 2023 · Application 17852439Pending
- Combination Therapy For C3 InhibitionJan 12, 2023 · Application 17719074Pending
- Rnas For Complement InhibitionNov 29, 2022 · US 11,510,939Granted
- Complement Inhibitor Dosing RegimensSep 8, 2022 · Application 17628084Pending
- Methods And Compositions For Cancer Treatment And Treatment SelectionAug 11, 2022 · Application 17480721Pending
- Cell-penetrating Compstatin Analogs And Uses ThereofAug 9, 2022 · US 11,407,789Granted
- Combination Therapy For C3 InhibitionMay 24, 2022 · US 11,338,013Granted
- Cell-reactive, Long-acting, Or Targeted Compstatin Analogs And Related Compositions And MethodsApr 5, 2022 · US 11,292,815Granted
- Detection Of High Risk DrusenApr 5, 2022 · US 11,291,407Granted
- Compositions And Methods Relating To C5L2Mar 24, 2022 · Application 17355029Pending
Related companies, and why
- NABsys IncSimilar federal contract value in Biotech · null in contracts
- Unity BiotechnologySimilar federal contract value in Biotech · null in contracts
- QT HOLDING CORPSimilar federal contract value in Biotech · null in contracts
- DRIVE THERAPEUTICS, L.L.C.Similar federal contract value in Biotech · null in contracts
- PALENA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Trove Labs IncSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .